newsfilter
← Latest News
GlobeNewswire·

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

• LAVA-1207 for the treatment of prostate cancer will continue as the lead program• LAVA-051 Phase 1/2a clinical trial will be discontinued• Associated cost savings and initiatives are expected to extend the cash runway